

## **Boston Scientific to Release Broad Range of Clinical Trial Results on Market-Leading TAXUS® Express<sup>2</sup>™ Coronary Stent System and Next-Generation TAXUS® Liberte™ System at Paris Course on Revascularization**

(May 20, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Paris Course on Revascularization (EuroPCR), which runs from May 24 to 27 in Paris.

"The data we will present at PCR is part of a continuum of consistent, durable results over a broad range of time, trials, lesions and patients," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "We expect this data will further solidify and justify our leadership in drug-eluting stents. We will present long-term data on our current drug-eluting stent platform, as well as first-time data on our next-generation product, TAXUS Liberte."

Tuesday, May 24 (all times are Paris time)

### **• TAXUS V IVUS Results.**

At 5:30 p.m., the Company will release nine-month intravascular ultrasound (IVUS) follow-up results from its TAXUS V clinical trial, which assesses the safety and efficacy of its TAXUS® Express<sup>2</sup>™ paclitaxel-eluting stent system. TAXUS V expands on the TAXUS IV pivotal trial and studies the most challenging lesions and highest-risk patients ever studied in a randomized, controlled clinical trial in the United States. The results will be presented by Neil Weissmann, M.D., at a session entitled "Deep Insight into Long Lesions" in Room 1 of the Palais des Congrès, 2 Place de la Porte Maillot, Paris. The Company will also issue a press release at that time.

### **• TAXUS VI Results.**

At 5:40 p.m., the Company will release two-year results from its TAXUS VI clinical trial, which evaluates the safety and efficacy of a moderate-release formulation of its TAXUS Express<sup>2</sup> paclitaxel-eluting stent in high-risk patients, including long lesions, small vessels and diabetics. (The Company's current commercialized product uses a slow-release formulation.) The results will be presented by Eberhard Grube, M.D., the study's Co-Principal Investigator, in Room 1. The Company will also issue a press release at that time.

Wednesday, May 25

### **• Symposium on Future of DES.**

At 12:00 p.m., the Company will host a symposium entitled "Toward New Frontiers: Using Data to Drive the Future" chaired by Keith Dawkins, M.D., in Room 1.

ATLAS results. During the symposium, Mark Turco, M.D., is scheduled to present 30-day results from Boston Scientific

---

<https://news.bostonscientific.com/news-releases?item=58667>